In general, the patterns of gene expression in PC-3 human prostate carcinoma cells treated with WP631 or co-treated with 2-DG plus WP631 were equivalent (see legend to Fig.4), although, as described above, down-regulation of Bcl-2 was observed after the co-treatments. This evidence concerns the gene BCL2 and prostate carcinoma.